Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use

US12215157B2 · kind B2 · utility

Assignee

• Dragonfly Therapeutics, Inc. · US

Inventors

• Gregory P. Chang · Medford, US
• Ann F. Cheung · Lincoln, US
• Asya Grinberg · Lexington, US
• Dhruv Kam Sethi · Westwood, US
• William Haney · Wayland, US
• Bianka Prinz · Lebanon, US
• Bradley M. Lunde · Lebanon, US
• Ronnie Wei · Weston, US
• Daniel Fallon · Winchester, US
• Steven O'Neil · Wayland, US

Key dates

• Filing date: Feb 20, 2019
• Grant date: Feb 4, 2025
• Expiry date: Jul 7, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.